This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Roberts, R. Articles by Sobel, B. E. Search for Related Content PubMed PubMed Citation Articles by Roberts, R. Articles by Sobel, B. E.

Circulation, Vol 52, 743-754, Copyright © 1975 by American Heart Association

ARTICLES

An improved basis for enzymatic estimation of infarct size

R Roberts, PD Henry and BE Sobel

Infarct size has been estimated from serial serum creatine phosphokinase (CPK) changes, but the contribution of noncardiac CPK may interfere. Results would also be influenced if CPK disappearance varied with hemodynamic changes. Since MB CPK is a marker more specific to myocardium. infarct size was estimated from serum MB changes in 16 patients. In addition, 21 chronically instrumented conscious dogs subjected to tachycardia, decreased cardiac output or hepatic or renal ischemia were studied to evaluate the dependence of CPK disappearance on hemodynamics. MB CPK in human tissue extracts and serum was quantified with a new, rapid, glass bead-batch adsorption technique, verified with CPK isoenzymes prepared from human myocardium. Among tissues surveyed, only myocardium contained appreciable MB CPK. Infarct size estimated from MB correlated with total serum CPK in patients with uncomplicated myocardial infarction (r=0.97, N=12). In patients with infarction given intramusclar injections, total CPK curves were distorted but MB CPK curves were not apparently affected. Hemodynamic alterations in conscious dogs did not markedly affect the disappearance rate (kd) of intravenously injected, radioactively labeled, canine myocardial CPK, although kd was shown to depend on reticuloendothelial system activity. These findings suggest that estimation of the extent of infarction based on serum MB CPK should be useful despite hemodynamic deterioration associated with infarction or interference of noncardiac CPK.

This article has been cited by other articles:

				H. Thibault, C. Piot, P. Staat, L. Bontemps, C. Sportouch, G. Rioufol, T. T. Cung, E. Bonnefoy, D. Angoulvant, J.-F. Aupetit, et al. Long-Term Benefit of Postconditioning Circulation, February 26, 2008; 117(8): 1037 - 1044. [Abstract] [Full Text] [PDF]

				E. Giannitsis, H. Steen, K. Kurz, B. Ivandic, A. C. Simon, S. Futterer, C. Schild, P. Isfort, A. S. Jaffe, and H. A. Katus Cardiac Magnetic Resonance Imaging Study for Quantification of Infarct Size Comparing Directly Serial Versus Single Time-Point Measurements of Cardiac Troponin T J. Am. Coll. Cardiol., January 22, 2008; 51(3): 307 - 314. [Abstract] [Full Text] [PDF]

				H. Thiele, M. J. Kappl, A. Linke, S. Erbs, E. Boudriot, A. Lembcke, D. Kivelitz, and G. Schuler Influence of time-to-treatment, TIMI-flow grades, and ST-segment resolution on infarct size and infarct transmurality as assessed by delayed enhancement magnetic resonance imaging Eur. Heart J., June 6, 2007; (2007) ehm173v1. [Abstract] [Full Text] [PDF]

				NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Circulation, April 3, 2007; 115(13): e356 - e375. [Full Text] [PDF]

				NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Clin. Chem., April 1, 2007; 53(4): 552 - 574. [Full Text] [PDF]

				R. J. Gibbons, U. S. Valeti, P. A. Araoz, and A. S. Jaffe The quantification of infarct size J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1533 - 1542. [Abstract] [Full Text] [PDF]

				K. W. Baran, M. Nguyen, G. R. McKendall, C. T. Lambrew, G. Dykstra, S. T. Palmeri, R. J. Gibbons, S. Borzak, B. E. Sobel, S. G. Gourlay, et al. Double-Blind, Randomized Trial of an Anti-CD18 Antibody in Conjunction With Recombinant Tissue Plasminogen Activator for Acute Myocardial Infarction: Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) Study Circulation, December 4, 2001; 104(23): 2778 - 2783. [Abstract] [Full Text] [PDF]

				M.-L. L. Boumans, J. H.C. Diris, M. Nap, A. M.M. Muijtjens, J. G. Maessen, M. P. van Dieijen-Visser, and W. T. Hermens Creatine Kinase Isoenzyme MB (CKMB) Controversy: Perimortal Tissue Acidosis May Explain the Absence of CKMB in Myocardium at Autopsy Clin. Chem., September 1, 2001; 47(9): 1733 - 1735. [Full Text] [PDF]

				Y. Ishikawa, J. E. Saffitz, T. L. Mealman, A. M. Grace, and R. Roberts Reversible myocardial ischemic injury is not associated with increased creatine kinase activity in plasma Clin. Chem., March 1, 1997; 43(3): 467 - 475. [Abstract] [Full Text] [PDF]

				L. V. Philosophov Bayesian Decision Making Based on Measurements Containing Errors Med Decis Making, August 1, 1995; 15(3): 264 - 275. [Abstract] [PDF]

				T. D. Miller, T. F. Christian, M. R. Hopfenspirger, D. O. Hodge, B. J. Gersh, and R. J. Gibbons Infarct Size After Acute Myocardial Infarction Measured by Quantitative Tomographic 99mTc Sestamibi Imaging Predicts Subsequent Mortality Circulation, August 1, 1995; 92(3): 334 - 341. [Abstract] [Full Text]

				R Roberts, B. Sobel, and C. Parker Radioimmunoassay for creatine kinase isoenzymes Science, November 19, 1976; 194(4267): 855 - 857. [Abstract] [PDF]